A pulmonary hemorrhage is bleeding into the lungs, specifically into the tiny air sacs (alveoli) where oxygen exchange happens. The blood can come from the small vessels surrounding these air sacs, including capillaries, arterioles, and venules. When bleeding is widespread across both lungs rather than confined to one spot, it’s called diffuse alveolar hemorrhage, or DAH, which is the most serious form and can be life-threatening.
How Bleeding Starts in the Lungs
The walls of the alveoli are extremely thin, just one or two cells thick, so that oxygen and carbon dioxide can pass through easily. This thinness also makes them vulnerable. When something damages or inflames those walls, red blood cells leak out of the capillaries and flood the air sacs, interfering with breathing.
There are two main patterns this damage can take. In one, called pulmonary capillaritis, white blood cells (particularly neutrophils) invade the tissue around the capillaries and destroy the vessel walls. This is the more dangerous pattern and is typically driven by autoimmune conditions. In the other pattern, called bland pulmonary hemorrhage, blood leaks into the alveoli without any inflammation or visible damage to the vessel walls. This can happen with clotting disorders or certain medications.
Common Causes
Most cases of diffuse alveolar hemorrhage trace back to an immune system problem. The body’s defenses mistakenly attack the blood vessels in the lungs. The most common autoimmune triggers include:
- ANCA-associated vasculitis: a group of conditions where antibodies cause inflammation in small blood vessels throughout the body, including the lungs and kidneys
- Goodpasture syndrome: the immune system produces antibodies that specifically target the basement membrane in the lungs and kidneys
- Lupus (SLE): a systemic autoimmune disease that can affect nearly any organ, with lung hemorrhage as a serious complication
- Antiphospholipid syndrome: an autoimmune clotting disorder that can damage pulmonary vessels
Infections are another frequent trigger, particularly in people with weakened immune systems. Pulmonary hemorrhage can also occur in patients who have received bone marrow or stem cell transplants, where conditioning treatments and the engraftment process itself contribute to lung damage.
Non-Immune Triggers
Not all pulmonary hemorrhage comes from autoimmune disease. Blood-thinning medications can raise the risk, especially at higher doses or in combination with other drugs. Cocaine use damages blood vessels through multiple pathways: it injures the vessel lining directly, promotes abnormal clotting, and elevates compounds that trigger platelet clumping. Certain toxic exposures and severe heart failure can also cause blood to back up into the lungs and leak into the alveoli.
Symptoms and Warning Signs
The classic presentation involves three hallmarks: coughing up blood (hemoptysis), iron-deficiency anemia, and hazy white patches on a chest X-ray. In practice, though, not everyone shows all three at once, especially children. Some people never cough up visible blood because the bleeding stays deep in the lung tissue.
An acute episode tends to come on suddenly with severe shortness of breath and bloody or rust-colored sputum. Breathing becomes rapid and labored, and oxygen levels drop quickly. In chronic or recurring cases, the picture looks different. Anemia develops gradually over weeks or months, sometimes before any lung symptoms appear, causing fatigue, pale skin, and exercise intolerance. A persistent cough and mild breathlessness may be the only clues. In some patients with idiopathic pulmonary hemosiderosis, iron-deficiency anemia precedes all other symptoms by many months, making early diagnosis difficult.
How It Is Diagnosed
Chest imaging is usually the first step. X-rays or CT scans show diffuse, hazy opacities across both lungs, a pattern sometimes described as “ground glass.” But this appearance can mimic pneumonia or fluid overload, so imaging alone isn’t enough.
The most definitive bedside test is bronchoalveolar lavage (BAL). A thin, flexible scope is passed into the airways, and small amounts of sterile fluid are flushed in and then suctioned back out. In pulmonary hemorrhage, the fluid comes back progressively bloodier with each wash. Under a microscope, pathologists look for macrophages (immune cells) that have absorbed iron from red blood cells, staining them with a dye called Prussian blue. When at least 20% of the recovered macrophages contain iron, the diagnosis of alveolar hemorrhage is confirmed.
Blood tests help identify the underlying cause. Doctors check for specific antibodies linked to vasculitis, Goodpasture syndrome, and lupus. Kidney function tests are also important because many of the same conditions that cause lung bleeding simultaneously damage the kidneys.
Severity and Prognosis
The volume of blood loss matters enormously. There is no universal cutoff for “massive” hemoptysis. Published thresholds range from 100 mL to over 1,000 mL within 24 hours, though many specialists use 600 mL per day as the working definition. At that level, the immediate risk shifts from blood loss to suffocation, as blood fills the airways faster than the body can clear it.
Diffuse alveolar hemorrhage carries a sobering mortality rate. In severe cases requiring mechanical ventilation, mortality can reach 70% or higher, often from a combination of organ failure and secondary infection. In one large study, 54% of intubated DAH patients died within 30 days, and 66% within 60 days. Patients who did not need intubation fared significantly better, with 30-day mortality around 13%. Early recognition and treatment make a meaningful difference in survival.
Treatment Approach
Treatment has three priorities: keep the patient alive, stop the bleeding, and treat whatever caused it.
Supportive care comes first. This means supplemental oxygen or, in severe cases, mechanical ventilation. Ventilators can be set to apply extra pressure that compresses the tiny bleeding vessels, creating a tamponade effect that slows blood loss. Blood transfusions correct anemia, and any clotting abnormalities are addressed.
For immune-mediated causes, high-dose corticosteroids are the cornerstone and are started as soon as possible. The goal is to rapidly suppress the inflammatory attack on the lung vessels. Additional immunosuppressive drugs are often added depending on the specific underlying disease. In conditions like Goodpasture syndrome or severe vasculitis, plasmapheresis (a procedure that filters harmful antibodies out of the blood) is used alongside medication. Each session replaces one to one-and-a-half times the total plasma volume, typically performed daily or every other day for about two weeks.
Long-term management depends on the cause. Many patients require months of immunosuppressive therapy to prevent recurrence. For vasculitis-related hemorrhage, maintenance treatment may last years.
Pulmonary Hemorrhage in Children
In children, pulmonary hemorrhage is rare, occurring at a rate of roughly 0.24 to 1.26 cases per million. When no autoimmune disease, infection, or other identifiable cause is found, the diagnosis is idiopathic pulmonary hemosiderosis (IPH), a condition characterized by repeated episodes of alveolar bleeding without a clear trigger.
Children with IPH often present differently than adults. The classic triad of hemoptysis, anemia, and lung infiltrates is less reliably present. Instead, unexplained iron-deficiency anemia and chronic cough may dominate the picture for months before lung involvement becomes obvious. Diagnosis requires ruling out all other causes and confirming iron-laden macrophages on bronchoalveolar lavage.
Treatment follows a similar pattern to adult care: corticosteroids during acute flares, then a maintenance dose that may continue for 18 to 24 months. The steroid dose is gradually tapered over weeks as lung opacities clear. If steroids alone aren’t enough, other immunosuppressive agents like azathioprine or hydroxychloroquine may be added. Because IPH tends to recur, children need long-term monitoring for both lung function and anemia.